Subjects randomized to treatment with human albumin will receive a total of 1.5 g/kg of albumin at the time of enrollment and 1.0 g/kg on day three of the treatment protocol. To maintain blinding, the research pharmacy will prepare the 25% albumin solution in order to be identical in volume and color to the dextran 70 through the use of a dextrose diluent. Because of the different dosing schedules between the two treatment arms in this study, equivolume placebo doses of dextrose (5%) will be given on day two when an active treatment dose is not scheduled in the albumin arm. Dextrose will be used to avoid the sodium load and potential mild plasma volume expansion associated with saline infusion.